Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.
Feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteases (PRs) share only 23% amino acid identity and exhibit distinct specificities yet have very similar 3-dimensional structures. Chimeric PRs in which HIV residues were substituted in structurally equivalent positions in FIV PR were prepared in order to study the molecular basis of PR specificity. Previous in vitro analyses showed that such substitutions dramatically altered the inhibitor specificity of mutant PRs but changed the rate and specificity of Gag cleavage so that chimeric FIVs were not infectious. Chimeric PRs encoding combinations of the I37V, N55M, M56I, V59I, L97T, I98P, Q99V, and P100N mutations were cloned into FIV Gag-Pol, and those constructs that best approximated the temporal cleavage pattern generated by wild-type FIV PR, while maintaining HIV-like inhibitor specificity, were selected. Two mutations, M56I and L97T, were intolerant to change and caused inefficient cleavage at NC-p2. However, a mutant PR with six substitutions (I37V, N55M, V59I, I98P, Q99V, and P100N) was selected and placed in the context of full-length FIV-34TF10. This virus, termed YCL6, had low-level infectivity ex vivo, and after passage, progeny that exhibited a higher growth rate emerged. The residue at the position of one of the six mutations, I98P, further mutated on passage to either P98H or P98S. Both PRs were sensitive to the HIV-1 PR inhibitors lopinavir (LPV) and darunavir (DRV), as well as to the broad-based inhibitor TL-3, with 50% inhibitory concentrations (IC(50)) of 30 to 40 nM, consistent with ex vivo results obtained using mutant FIVs. The chimeras offer an infectivity system with which to screen compounds for potential as broad-based PR inhibitors, define structural parameters that dictate specificity, and investigate pathways for drug resistance development.
Lin
Ying-Chuan
YC
Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
Torbett
Bruce E
BE
Elder
John H
JH
D019943:Amino Acid Substitution / Q000235:genetics; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000235:genetics*; D002415:Cats; D002460:Cell Line; D000069454:Darunavir; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D016089:Immunodeficiency Virus, Feline / Q000187:drug effects / Q000235:genetics*; D020128:Inhibitory Concentration 50; D061466:Lopinavir; D011744:Pyrimidinones / Q000494:pharmacology; D011994:Recombinant Proteins / Q000235:genetics; D011995:Recombination, Genetic; D013449:Sulfonamides / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects*
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D011994:Recombinant Proteins; D013449:Sulfonamides; D061466:Lopinavir; D016282:Aspartic Acid Endopeptidases; C095555:FIV protease; D016333:HIV Protease; C514803:p16 protease, Human immunodeficiency virus 1; D000069454:Darunavir
Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):939-44
9448264
AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):797-801
9643379
J Virol. 1995 Jun;69(6):3407-19
7745687
Virology. 2004 Sep 15;327(1):83-92
15327900
J Virol. 2005 Aug;79(16):10638-49
16051856
Expert Opin Ther Targets. 2009 Aug;13(8):895-908
19534569
Bioorg Med Chem. 2003 May 1;11(9):2025-40
12670654
J Virol. 2000 May;74(10):4710-20
10775609
J Virol. 1999 Jun;73(6):4991-5000
10233961
Chembiochem. 2005 Jul;6(7):1167-9
15934050
Bioorg Med Chem. 2001 May;9(5):1185-95
11377177
Virology. 2000 Sep 1;274(2):391-401
10964781
Retrovirology. 2004 Nov 19;1:38
15555065
Infect Agents Dis. 1993 Dec;2(6):361-74
8012737
J Virol. 2001 Oct;75(19):9502-8
11533212
Mol Cell Biol. 1987 Jan;7(1):379-87
3031469
Antiviral Res. 2007 Dec;76(3):203-21
17673305
Antimicrob Agents Chemother. 2003 Feb;47(2):759-69
12543689
Curr Drug Targets Infect Disord. 2003 Dec;3(4):295-309
14754431
J Virol. 2003 Jun;77(12):6589-600
12767979
J Virol. 1994 Dec;68(12):8017-27
7966591
Curr Top Microbiol Immunol. 1995;202:167-86
7587362
Antiviral Res. 2010 Jan;85(1):59-74
19853627
PLoS One. 2009;4(3):e4724
19266092
J Virol. 2002 Aug;76(15):7398-406
12097552
Retrovirology. 2007 Jan 09;4:1
17212810
AIDS Rev. 2008 Jul-Sep;10(3):131-42
18820715
Anal Biochem. 1997 Dec 15;254(2):226-30
9417781
Biochemistry. 1997 Sep 2;36(35):10696-708
9271500
Vet Immunol Immunopathol. 2008 May 15;123(1-2):3-13
18289701
J Virol. 2009 Sep;83(17):8536-43
19515760
J Virol. 2006 Aug;80(16):7832-43
16873240
Bioorg Med Chem Lett. 2001 Jan 22;11(2):219-22
11206463
Proc Natl Acad Sci U S A. 1989 Aug;86(15):5743-7
2762293
Expert Opin Pharmacother. 2008 Sep;9(13):2363-75
18710360
Curr Opin HIV AIDS. 2007 Mar;2(2):108-15
19372875
Nat Struct Biol. 1995 Jun;2(6):480-8
7664111
Acta Crystallogr D Biol Crystallogr. 2007 Aug;63(Pt 8):866-75
17642513
PLoS Pathog. 2009 Mar;5(3):e1000345
19300491
Curr Drug Targets Infect Disord. 2002 Mar;2(1):37-50
12462152
J Virol. 2004 May;78(9):4525-32
15078933
Adv Virus Res. 1995;45:225-47
7793326
Biotechniques. 1990 Apr;8(4):404-7
2340178
J Virol. 1997 Aug;71(8):5723-32
9223458
Handb Exp Pharmacol. 2009;(189):85-110
19048198
J Virol. 2001 Oct;75(19):9458-69
11533208
Pharmacol Ther. 2000 May;86(2):145-70
10799712
J Virol. 2008 Mar;82(5):2106-19
18094166
J Med Chem. 2008 Oct 23;51(20):6263-70
18823110
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60
14573704
Bioorg Med Chem. 2006 Feb 15;14(4):1058-62
16275107
Top HIV Med. 2008 Dec;16(5):138-45
19106428
Chembiochem. 2003 Nov 7;4(11):1246-8
14613121